Adverse events and drug–drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure

References

• Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287–1302. doi: 10.1080/17425255.2018.1551877
   PubMed Web of Science ®Google Scholar
• FDA. accessed on 2023 Sep 19th Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216203Orig1s000TOC.cfm
   Google Scholar
• Gu N, Park SI, Chung H, et al. Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Transl Clin Pharmacol. 2020;28(1):17–33. doi: 10.12793/tcp.2020.28.e4
   PubMedGoogle Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on Biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463–1476. doi: 10.1161/CIRCULATIONAHA.119.042929
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–722. doi: 10.1002/ejhf.1713
   PubMed Web of Science ®Google Scholar
• Jensen J, Omar M, Kistorp C, et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. Am Heart J. 2020;228:47–56. doi: 10.1016/j.ahj.2020.07.011
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. doi: 10.1056/NEJMoa2030183
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. doi: 10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar
• Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation. 2022;146(4):289–298. doi: 10.1161/CIRCULATIONAHA.122.059038
   PubMed Web of Science ®Google Scholar
• Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–574. doi: 10.1038/s41591-021-01659-1
   PubMed Web of Science ®Google Scholar
• Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. Diabetes Metab Syndr. 2022;16(2):102417. doi: 10.1016/j.dsx.2022.102417
   PubMed Web of Science ®Google Scholar
• EMA accessed on 2023 Jul 7th Available from: https://www.ea.europa.eu/en/medicines/human/EPAR/forxiga
   Google Scholar
• FDA. accessed on 2023 Jul 7th. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023
   Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American heart association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;28(1):ahead195. doi: 10.15829/1560-4071-2023-5168
   Google Scholar
• Markham A, Keam SJ. Sotagliflozin: first global approval. Drugs. 2019;79(9):1023–1029. doi: 10.1007/s40265-019-01146-5
   PubMed Web of Science ®Google Scholar
• Pelletier R, Ng K, Alkabbani W, et al. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther Adv Drug Saf. 2021;12:2042098621989134. doi: 10.1177/2042098621989134
   Web of Science ®Google Scholar
• Hwang JG, Jeong SI, Kim YK, et al. Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Transl Clin Pharmacol. 2022;30(4):212–225. doi: 10.12793/tcp.2022.30.e23
   PubMedGoogle Scholar
• Kasichayanula S, Liu X, Griffen SC, et al. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diab Obes Metab. 2013;15(3):280–283. doi: 10.1111/dom.12024
   PubMed Web of Science ®Google Scholar
• Matharu K, Chana K, Ferro CJ, et al. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions. Pharmacol Res Perspect. 2021;9(5):e00867. doi: 10.1002/prp2.867
   PubMed Web of Science ®Google Scholar
• Okada J, Yamada E, Saito T, et al. Dapagliflozin inhibits cell adhesion to collagen I and IV and increases ectodomain proteolytic cleavage of DDR1 by increasing ADAM10 activity. Molecules. 2020;25(3):495. doi: 10.3390/molecules25030495
   PubMed Web of Science ®Google Scholar
• Macha S, Koenen R, Sennewald R, et al. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Clin Ther. 2014;36(2):280–90.e1. doi: 10.1016/j.clinthera.2014.01.003
   PubMed Web of Science ®Google Scholar
• Qiu M, Ding LL, Zhang M, et al. Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res. 2021;18(2):14791641211011016. doi: 10.1177/14791641211011016
   Web of Science ®Google Scholar
• Caparrotta TM, Greenhalgh AM, Osinski K, et al. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. Diabetes Ther. 2021;12(4):991–1028. doi: 10.1007/s13300-021-01004-2
   PubMed Web of Science ®Google Scholar
• Zhao B, Shen J, Zhao J, et al. Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study. J Diabetes Investig. 2021;12(8):1400–1407. doi: 10.1111/jdi.13481
   PubMed Web of Science ®Google Scholar
• Avgerinos I, Karagiannis T, Kakotrichi P, et al. Sotagliflozin for patients with type 2 diabetes: a systematic review and meta-analysis. Diab Obes Metab. 2022;24(1):106–114. doi: 10.1111/dom.14555
   PubMed Web of Science ®Google Scholar
• Fuchs Andersen C, Omar M, Glenthøj A, et al. Effects of empagliflozin on erythropoiesis in heart failure: data from the empire HF trial. Eur J Heart Fail. 2023;25(2):226–234. doi: 10.1002/ejhf.2735
   PubMed Web of Science ®Google Scholar
• Tukker M, Bruwiere E, Bos S, et al. SGLT2 inhibitor–related polycythemia in a patient with chronic heart failure: a potential severe adverse event. Circ Heart Fail. 2023;16(7):e010613. doi: 10.1161/CIRCHEARTFAILURE.123.010613
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Sasabuchi Y, Horikita S, et al. The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: a retrospective cohort study. BMC Endocr Disord. 2022;22(1):209. doi: 10.1186/s12902-022-01126-z
   PubMed Web of Science ®Google Scholar
• Tran BA, Updike WH, Bullers K, et al. Sodium-glucose cotransporter 2 inhibitor use associated with Fournier’s gangrene: a review of case reports and spontaneous post-marketing cases. Clin Diabetes. 2022;40(1):78–86. doi: 10.2337/cd21-0015
   PubMedGoogle Scholar
• Vargo E, Leone G, Barat O, et al. A case of Fournier’s gangrene following a large-volume hydrocelectomy in a diabetic patient managed with SGLT-2 inhibitor therapy. Urol Case Rep. 2021;39:101834. doi: 10.1016/j.eucr.2021.101834
   PubMed Web of Science ®Google Scholar
• Younes AM, Salem M, Maraey A, et al. Safety outcomes of SGLT2i in the heart failure trials: a systematic review and meta-analysis. Int J Cardiol. 2022;366:51–56. doi: 10.1016/j.ijcard.2022.06.059
   PubMed Web of Science ®Google Scholar
• Borovac JA, Kurir T, Mustapic I, et al. SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: a pooled analysis examining safety endpoints. Kardiol Pol. 2022;80(2):198–201. doi: 10.33963/KP.a2021.0172
   PubMed Web of Science ®Google Scholar
• Böhm M, Butler J, Krawczyk M, et al. Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Eur J Heart Fail. 2023;25(8):1375–1383. doi: 10.1002/ejhf.2922
   PubMed Web of Science ®Google Scholar
• Adamson C, Cowan LM, de Boer RA, et al. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. Eur J Heart Fail. 2022;24(10):1856–1868. doi: 10.1002/ejhf.2649
   PubMed Web of Science ®Google Scholar
• Senoo M, Tone A, Imai Y, et al. Marked hypertriglyceridemia in a patient with type 2 diabetes receiving SGLT2 inhibitors. Acta Med Okayama. 2021;75(1):103–107. doi: 10.18926/AMO/61441
   PubMed Web of Science ®Google Scholar
• Schmidt H, Schlitt A. Hypoglykämie unter SGLT2-inhibition bei einem patienten mit HFrEF ohne diabetes mellitus [hypoglycemia in a patient treated with a SGLT2-inhibitor with HFrEF without diabetes mellitus]. Dtsch Med Wochenschr. 2022;147(18):1195–1198. doi: 10.1055/a-1892-4104
   PubMedGoogle Scholar
• Zeng YH, Liu SC, Lee CC, et al. Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin. Sci Rep. 2022;12(1):17065. doi: 10.1038/s41598-022-21486-9
   PubMed Web of Science ®Google Scholar
• Oriot P, Hermans MP, Beauloye C, et al. Unsuspected diabetic ketoacidosis after myocardial infarction in a patient treated with SGLT2 inhibitor increased length of stay in the hospital: how can it be prevented? A case report. Eur Heart J Case Rep. 2023;7(8):ytad336. doi: 10.1093/ehjcr/ytad336
   PubMedGoogle Scholar
• Rathore A, Gupta N, Kahn C, et al. Euglycemic diabetic ketoacidosis caused by empagliflozin complicated by failure to thrive in a geriatric patient. Arch Clin Cases. 2023;10(2):89–92. doi: 10.22551/2023.39.1002.10248
   PubMedGoogle Scholar
• Iesaka H, Nomoto H, Atsumi T. Alcoholic ketoacidosis manifesting with hypoglycemia exacerbated by an SGLT2 inhibitor in a nondiabetic patient. Mayo Clin Proc. 2023;98(6):947–948. doi: 10.1016/j.mayocp.2023.04.003
   PubMed Web of Science ®Google Scholar
• Seki H, Watanabe H, Yorozu T. Postoperative ketoacidosis with hypoglycemia in a nondiabetic patient taking dapagliflozin for heart failure: a case report. A A Pract. 2022;16(3):e01570. doi: 10.1213/XAA.0000000000001570
   PubMedGoogle Scholar
• Cha BM, Davoudi R, DiVita MC, et al. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis after orthotopic heart Transplant in a prediabetic patient: a case report. Transplant Proc. 2021;53(8):2636–2639. doi: 10.1016/j.transproceed.2021.08.017
   PubMed Web of Science ®Google Scholar
• Shi N, Shi Y, Xu J, et al. SGLT-2i and risk of malignancy in type 2 diabetes: a meta-analysis of randomized controlled trials. Front Public Health. 2021;9:668368. doi: 10.3389/fpubh.2021.668368
   PubMed Web of Science ®Google Scholar
• Tang H, Dai Q, Shi W, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862–1872. doi: 10.1007/s00125-017-4370-8
   PubMed Web of Science ®Google Scholar
• Chung CT, Lakhani I, Chou OHI, et al. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study. Cancer Med. 2023;12(11):12299–12315. doi: 10.1002/cam4.5927
   PubMed Web of Science ®Google Scholar
• Gao F, Hall S, Bach LA. Myopathy secondary to empagliflozin therapy in type 2 diabetes. Endocrinol Diabetes Metab Case Rep. 2020;12:20–0017. doi: 10.1530/EDM-20-0017
   Google Scholar
• Stella M, Biassoni E, Fiorillo C, et al. A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors. Neurol Sci. 2022;43(7):4567–4570. doi: 10.1007/s10072-022-06046-3
   PubMed Web of Science ®Google Scholar
• Butt JH, Kondo T, Yang M, et al. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023;44(24):2170–2183. doi: 10.1093/eurheartj/ehad276
   PubMed Web of Science ®Google Scholar
• Frent I, Bucsa C, Leucuta D, et al. An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: a VigiBase study. Pharmacoepidemiol Drug Saf. 2021;30(10):1428–1440. doi: 10.1002/pds.5313
   PubMed Web of Science ®Google Scholar
• Palapra H, Viswam SK, Kalaiselvan V, et al. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. Int J Clin Pharm. 2022;44(6):1425–1433. doi: 10.1007/s11096-022-01476-7
   PubMed Web of Science ®Google Scholar
• Rampersad C, Kraut E, Whitlock RH, et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study. Am J Kidney Dis. 2020;76(4):471–9.e1. doi: 10.1053/j.ajkd.2020.03.019
   PubMed Web of Science ®Google Scholar
• Frent I, Leucuta D, Bucsa C, et al. A description of acute renal failure and nephrolithiasis associated with sodium-glucose co-transporter 2 inhibitor use: a VigiBase study. Front Pharmacol. 2022;13:925805. doi: 10.3389/fphar.2022.925805
   PubMed Web of Science ®Google Scholar
• Pan R, Zhang Y, Wang R, et al. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. PLoS One. 2022;17(12):e0279889. doi: 10.1371/journal.pone.0279889
   PubMedGoogle Scholar
• Goto Y, Otsuka Y, Ashida K, et al. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use. Endocr Connect. 2020;9(7):599–606. doi: 10.1530/EC-20-0082
   PubMed Web of Science ®Google Scholar
• Buch A, Eldor R, Kis O, et al. The effect of circuit resistance training, empagliflozin or “vegeterranean diet” on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial). BMC Geriatr. 2019;19(1):228. doi: 10.1186/s12877-019-1219-7
   PubMed Web of Science ®Google Scholar
• Horibe K, Morino K, Miyazawa I, et al. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: a randomized, clinical trial. Diabet Res Clin Pract. 2022;186:109781. doi: 10.1016/j.diabres.2022.109781
   PubMed Web of Science ®Google Scholar
• Yasuda M, Iizuka K, Kato T, et al. Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report. J Diabetes Investig. 2020;11(3):745–747. doi: 10.1111/jdi.13137
   PubMed Web of Science ®Google Scholar
• Dyson SM, Patel PU, Igali L, et al. Bullous pemphigoid in a patient with a neuropsychological disorder and a possible novel drug trigger: a case report and review of the literature. Skin Health Dis. 2020;2(4):e176. doi: 10.1002/ski2.176
   Google Scholar
• To D, Bradshaw S, Lipson J. Case report of empagliflozin-induced Cutaneous Polyarteritis Nodosa. J Cutan Med Surg. 2018;22(5):516–518. doi: 10.1177/1203475418760457
   PubMed Web of Science ®Google Scholar
• Brock GM, Lane SM, Roosevelt TS. Emphysematous Cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin. AACE Clin Case Rep. 2022;8(4):163–165. doi: 10.1016/j.aace.2022.04.002
   PubMedGoogle Scholar
• Fujiki S, Iijima K, Okabe M, et al. Placebo-controlled, Double-blind study of empagliflozin (EMPA) and implantable cardioverter-defibrillator (EMPA-ICD) in patients with type 2 diabetes (T2DM): rationale and design. Diabetes Ther. 2020;11(11):2739–2755. doi: 10.1007/s13300-020-00924-9
   PubMed Web of Science ®Google Scholar
• Younis A, Arous T, Klempfner R, et al. Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices. J Cardiovasc Electrophysiol. 2023;34(8):1595–1604. doi: 10.1111/jce.15996
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharma. Modul 4 A. Dossier zur Nutzenbewertung gemäß § 35a SGB, 12.07.2021. accessed on Jul 30th 2023. Available from: https://www.google.at/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwizgoDq6LWAAxUtXvEDHQZeDtIQFnoECBIQAQ&url=https%3A%2F%2Fwww.g-ba.de%2Fdownloads%2F92-975-4931%2F2021_07_12_Modul4A_Empagliflozin.pdf&usg=AOvVaw3jwgJirBpckvxj0G_Q2HnA&opi=89978449
   Google Scholar
• Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727–3738. doi: 10.1093/eurheartj/ehab560
   PubMed Web of Science ®Google Scholar
• Mounsey SJ, Teo YX, Calonje JE, et al. Gliflozin (SGLT2 inhibitor) induced vulvitis. Int J Dermatol. 2023;62(1):62–65. doi: 10.1111/ijd.16449
   PubMed Web of Science ®Google Scholar
• Engelhardt K, Ferguson M, Rosselli JL. Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. Ann Pharmacother. 2021;55(4):543–548. doi: 10.1177/1060028020951928
   PubMed Web of Science ®Google Scholar
• Copur S, Yildiz A, Basile C, et al. Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury? J Nephrol. 2023;36(1):31–43. doi: 10.1007/s40620-022-01422-w
   PubMed Web of Science ®Google Scholar
• Schumacher C. Severe hypotension with concomitant sodium-glucose co-transporter-2 inhibitor and angiotensin receptor-neprilysin inhibitor therapy in a patient with heart failure reduced ejection fraction: a case report. J Pharm Pract. 2022;8971900221142686:089719002211426. doi: 10.1177/08971900221142686
   Google Scholar
• Konta Y, Saito E, Sato K, et al. Tubulointerstitial nephritis after using a sodium-glucose cotransporter 2 inhibitor. Intern Med. 2022;61(21):3239–3243. doi: 10.2169/internalmedicine.9011-21
   PubMed Web of Science ®Google Scholar
• Zheng XD, Qu Q, Jiang XY, et al. Effects of dapagliflozin on cardiovascular events, death, and safety outcomes in patients with heart failure: a meta-analysis. Am J Cardiovasc Drugs. 2021;21(3):321–330. doi: 10.1007/s40256-020-00441-x
   PubMed Web of Science ®Google Scholar
• Kovesdy C, Schmedt N, Folkerts K, et al. Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors. BMC Med. 2022;20(1):2. doi: 10.1186/s12916-021-02191-2
   PubMed Web of Science ®Google Scholar
• Wendt R, Schmerler D, Müller-Hechler C, et al. Candida sepsis from local infection in a patient with a urostomy on SGLT2 inhibitor therapy. Int J Infect Dis. 2020;98:227–229. doi: 10.1016/j.ijid.2020.06.073
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849–5. doi: 10.1210/jc.2015-1884
   PubMed Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol. 2021;16(8):1284–1291. doi: 10.2215/CJN.17621120
   PubMed Web of Science ®Google Scholar
• Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104(8):3077–3087. doi: 10.1210/jc.2019-00139
   PubMed Web of Science ®Google Scholar
• Kim YG, Jeon JY, Han SJ, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Diab Obes Metab. 2018;20(8):1852–1858. doi: 10.1111/dom.13297
   PubMed Web of Science ®Google Scholar
• Dorcely B, Nitis J, Schwartzbard A, et al. A case report: euglycemic diabetic ketoacidosis presenting as chest pain in a patient on a low carbohydrate diet. Curr Diabetes Rev. 2021;17(2):243–246. doi: 10.2174/1573399816666200316112709
   PubMed Web of Science ®Google Scholar
• Khunti K, Aroda VR, Bhatt DL, et al. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: a perspective based on the updated evidence. Diab Obes Metab. 2022;24(11):2071–2080. doi: 10.1111/dom.14805
   PubMed Web of Science ®Google Scholar
• Hagedorn JC, Wessells H. A contemporary update on Fournier’s gangrene. Nat Rev Urol. 2017;14(4):205–214. doi: 10.1038/nrurol.2016.243
   PubMed Web of Science ®Google Scholar
• Huttunen R, Sainio A, Hjelt A, et al. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos. Biomed Pharmacother. 2022;156:113882. doi: 10.1016/j.biopha.2022.113882
   PubMed Web of Science ®Google Scholar
• Skeik N, Elejla SA, Sethi A, et al. Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: a review. Vasc Med. 2023;28(1):62–76. doi: 10.1177/1358863X221143811
   PubMed Web of Science ®Google Scholar
• Blau JE, Taylor SI. Adverse effects of SGLT2 inhibitors on bone health. Nat Rev Nephrol. 2018;14(8):473–474. doi: 10.1038/s41581-018-0028-0
   PubMed Web of Science ®Google Scholar
• Oates CP, Santos-Gallego CG, Smith A, et al. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: meta-analysis of randomized clinical trials. J Cardiovasc Electrophysiol. 2023;34(5):1277–1285. doi: 10.1111/jce.15894
   PubMed Web of Science ®Google Scholar
• Ellermann C, Uphoff J, Wolfes J, et al. Divergent safety profile of the SGLT2 inhibitors dapagliflozin and empagliflozin in a whole-heart model. Clin Res Cardiol. 2022. doi: 10.1007/s00392-022-02002-5
   Google Scholar
• Packer M, Cleland JGF. Combining iron Supplements with SGLT2 inhibitor-Stimulated erythropoiesis in heart failure: should we be worried about thromboembolic events? J Card Fail. 2023;29(3):403–406. doi: 10.1016/j.cardfail.2022.12.007
   PubMed Web of Science ®Google Scholar
• Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diab Obes Metab. 2013;15(5):432–440. doi: 10.1111/dom.12047
   PubMed Web of Science ®Google Scholar
• Crisafulli S, Cutroneo PM, Verhamme K, et al. Drug-induced urinary retention: an analysis of a national spontaneous adverse drug reaction reporting database. Eur Urol Focus. 2022;8(5):1424–1432. doi: 10.1016/j.euf.2021.07.001
   PubMedGoogle Scholar
• Alam K, Crowe A, Wang X, et al. Regulation of Organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-Mediated drug-drug interactions. Int J Mol Sci. 2018;19(3):855. doi: 10.3390/ijms19030855
   PubMed Web of Science ®Google Scholar
• Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35(3):226–235. doi: 10.1016/j.clinthera.2013.02.015
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163–177. doi: 10.1007/s12325-011-0098-x
   PubMed Web of Science ®Google Scholar
• Moldenhauer I, Pliquett RU, Kreft B, et al. Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium-glucose cotransporter 2 inhibitor - SGLT2-inhibitor). J Dtsch Dermatol Ges. 2019;17(4):456–458. doi: 10.1111/ddg.13807
   Google Scholar
• Liles JE, Flanigan K, Davis LS. Association of IL-17 inhibitor and SGLT2 inhibitor with Candida Pyelonephritis. Am J Med. 2021;134(11):e561–2. doi: 10.1016/j.amjmed.2021.05.033
   PubMedGoogle Scholar
• Lorenzo M, de la Espriella R, Cardells I, et al. Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure. Rev Esp Cardiol (Engl Ed). 2023;76(2):121–123. doi: 10.1016/j.recesp.2022.05.012
   PubMedGoogle Scholar
• Li MM, Shen WC, Li YJ, et al. Linezolid-induced pancytopenia in patients using Dapagliflozin: a case series. Infect Drug Resist. 2022;15:5509–5517. doi: 10.2147/IDR.S375694
   PubMed Web of Science ®Google Scholar
• Armstrong GP. Empagliflozin-mediated lithium excretion: a case study and clinical applications. Am J Case Rep. 2020;21:e923311.
   PubMed Web of Science ®Google Scholar
• Dyson V, Whyte I, Reimann F. Letter to the Editor: role of empagliflozin in chronic lithium toxicity. Aust Prescr. 2022;45(5):158. doi: 10.18773/austprescr.2022.062
   PubMed Web of Science ®Google Scholar
• Macha S, Lang B, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(11):973–980. doi: 10.5414/CP202117
   PubMed Web of Science ®Google Scholar
• Attallah N, Yassine L. Use of empagliflozin in recipients of kidney Transplant: a report of 8 cases. Transplant Proc. 2019;51(10):3275–3280. doi: 10.1016/j.transproceed.2019.05.023
   PubMed Web of Science ®Google Scholar
• Suetani Y, Arita Y, Iida Y, et al. Septic shock due to urinary tract infection in an immunosuppressed patient prescribed Dapagliflozin. Cureus. 2022;14(10):e30552. doi: 10.7759/cureus.30552
   PubMed Web of Science ®Google Scholar
• Miyauchi T. Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction. DARU, J Pharm Sci. 2020;28(1):419–421. doi: 10.1007/s40199-020-00333-0
   Web of Science ®Google Scholar
• Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diab Obes Metab. 2013;15(4):316–323. doi: 10.1111/dom.12028
   PubMed Web of Science ®Google Scholar
• Packer M. Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure. JACC Heart Fail. 2023;11(1):106–4. doi: 10.1016/j.jchf.2022.10.004
   PubMed Web of Science ®Google Scholar
• Nevola R, Villani A, Imbriani S, et al. Sodium-glucose co-transporters family: Current evidence, clinical applications and perspectives. Front Biosci (Landmark Ed). 2023;28(5):103. doi: 10.31083/j.fbl2805103
   PubMed Web of Science ®Google Scholar
• Wicik Z, Nowak A, Jarosz-Popek J, et al. Characterization of the SGLT2 interaction Network and its Regulation by SGLT2 inhibitors: a Bioinformatic analysis. Front Pharmacol. 2022;13:901340. doi: 10.3389/fphar.2022.901340
   PubMed Web of Science ®Google Scholar
• Scholl-Bürgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004;19(9):2394–2396. doi: 10.1093/ndt/gfh366
   PubMed Web of Science ®Google Scholar
• Calado J, Sznajer Y, Metzger D, et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant. 2008;23(12):3874–3879. doi: 10.1093/ndt/gfn386
   PubMed Web of Science ®Google Scholar
• Lee H, Han KH, Park HW, et al. Familial renal glucosuria: a clinicogenetic study of 23 additional cases. Pediatr Nephrol. 2012;27(7):1091–1095. doi: 10.1007/s00467-012-2109-9
   PubMed Web of Science ®Google Scholar
• Zannad F, Ferreira JP, Butler J, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J. 2022;43(48):4991–5002. doi: 10.1093/eurheartj/ehac495
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Murthy AC, Lee YH, et al. Mechanisms of sodium-glucose cotransporter 2 inhibition: insights from large-scale proteomics. Diabetes Care. 2020;43(9):2183–2189. doi: 10.2337/dc20-0456
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Fu Z, Jones P, et al. Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF. Circulation. 2022;146(11):808–818. doi: 10.1161/CIRCULATIONAHA.122.060402
   PubMed Web of Science ®Google Scholar
• Borzouei S, Moghimi H, Zamani A, et al. Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy. Hum Immunol. 2021;82(6):422–428. doi: 10.1016/j.humimm.2021.03.004
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–423. doi: 10.1093/ageing/afq034
   PubMed Web of Science ®Google Scholar
• Li R, Curtis K, Van C, et al. Why hospital-based healthcare professionals do not report adverse drug reactions: a mixed methods study using the theoretical domains framework. Eur J Clin Pharmacol. 2022;78(7):1165–1175. doi: 10.1007/s00228-022-03326-x
   PubMed Web of Science ®Google Scholar
• Sardella M, Belcher G, Lungu C, et al. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance. Ther Adv Drug Saf. 2021;12:20420986211038436. doi: 10.1177/20420986211038436
   Web of Science ®Google Scholar
• Al-Musawe L, Torre C, Guerreiro JP, et al. Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution. Eur J Clin Pharmacol. 2021;77(9):1397–1407. doi: 10.1007/s00228-021-03107-y
   PubMed Web of Science ®Google Scholar
• Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13(11):e006977. doi: 10.1161/CIRCHEARTFAILURE.120.006977
   PubMed Web of Science ®Google Scholar
• Lazzeroni D, Villatore A, Souryal G, et al. The aging heart: a molecular and clinical challenge. Int J Mol Sci. 2022;23(24):16033. doi: 10.3390/ijms232416033
   PubMed Web of Science ®Google Scholar
• Lunati ME, Cimino V, Gandolfi A, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183:106396. doi: 10.1016/j.phrs.2022.106396
   PubMed Web of Science ®Google Scholar
• Ramonfaur D, Skali H, Claggett B, et al. Bidirectional association between frailty and cardiac structure and function: the atherosclerosis risk in communities study. J Am Heart Assoc. 2023;12(15):e029458. doi: 10.1161/JAHA.122.029458
   PubMed Web of Science ®Google Scholar
• Mone P, Lombardi A, Gambardella J, et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care. 2022;45(5):1247–1251. doi: 10.2337/dc21-2434
   PubMed Web of Science ®Google Scholar
• Yabe D, Shiki K, Homma G, et al. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diab Obes Metab. 2023 Aug 25; doi: 10.1111/dom.15249
   Google Scholar
• Pottegård A, Friis S, Stürmer T, et al. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol. 2018;122(5):451–459. doi: 10.1111/bcpt.12946
   PubMed Web of Science ®Google Scholar
• Lund M, Petersen TS, Dalhoff KP, et al. Clinical implications of P-Glycoprotein modulation in drug-drug interactions. Drugs. 2017;77(8):859–883. doi: 10.1007/s40265-017-0729-x
   PubMed Web of Science ®Google Scholar